David S. Baskin, MD, FAANS, FACS

Kenneth R. Peak Presidential Distinguished Chair & Program Director, Neurosurgery Residency, Department of Neurosurgery
Professor of Neurosurgery, Academic Institute
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Peak Center Lab


Biography

Dr. Baskin began his research career while still a resident at the University of California San Francisco (UCSF). In 1982, he spent a year as a Research Associate at the University of Capetown Medical School and Groote Schuur Hospital in Capetown, South Africa. The following year, Dr. Baskin returned to UCSF and served as a Research Associate in the Hormone Research Laboratory. After completing his residency, Dr. Baskin was appointed as Assistant Professor of Neurological Surgery and Assistant Professor of the Center for Biotechnology at Baylor College of Medicine, with a joint appointment as Chief of Neurological Surgery at the VA Hospital. In 1994 he was promoted to Professor at Baylor College of Medicine in the departments of Neurosurgery and Anesthesiology, positions he held until 2005 when his academic career transitioned to Methodist.

Dr. Baskin has received many national and international honors and awards. He has served as principal investigator on numerous research projects funded by private, state and federal sources, resulting in multiple patents and patent applications. He has also chaired or served on review panels and advisory councils for private, state and federal agencies. Dr. Baskin has published over 100 scientific manuscripts and book chapters and currently serves as Program Director in Houston Methodist Neurological Institute, as well as Professor of Neurosurgery at Weill Cornell Medical College, and Research Professor at the University of Houston in both the Cullen College of Engineering's Department of Electrical and Computer Engineering and the School of Pharmacy.

Description of Research

The long-term goals of the Neurosurgery Research Laboratory are to elucidate the DNA mechanisms in various types of neurological disease, and to develop novel diagnostics and treatments for primary brain tumors and autistic spectrum disorder. Dr. Baskin has recently developed methodologies to quantify the levels of different types of DNA damage and of labeled antibody staining in the field of fluorescence microscopy, using a new type of labeled tissue phantoms. His laboratory has introduced innovative techniques that allow the quantification of five different types of DNA damage; blunt ended breaks, overhanging breaks, 3'OH ends and nicks, 3'PO4 ends and nicks and also damaged/oxidized DNA bases. These techniques are in the process of being patented.

In addition, and in conjunction with these tools for examining DNA damage, his research group is pursuing mitochondrially targeted chemotherapeutic agents. These pro-drug agents are activated by enzyme systems known to be up-regulated in certain cancers. The active drug then attacks mitochondrial DNA and mitochondrial RNA; causing loss of mitochondria and cell death. In collaboration with Dr. James Tour, of the Smalley Institute for Nanoscale Science and Technology at Rice University, Dr. Baskin's group is investigating the use of nanoscale carbon clusters in numerous biomedical applications including as a means to deliver chemotherapeutic agents that are targeted specifically to cancer cells, as well as use as cellular protective agents.

The relationship between environmental pollutants and Autism is also a major research topic being pursued by Dr. Baskin and his group. They have been evaluating the role of possible causative agents, including the classical toxin, organic mercury, which he has shown to have high toxicity in a subgroup of autistic individuals. A second class of causative agents being investigated by his group are hormone disrupting agents such as the agro-chemicals DDT and Atrazine. Their preliminary data suggests that there is major difference in the response of cells from autistic individuals, compared to external controls.

Areas Of Expertise

Stroke Neurological surgery Brain tumors
Education & Training

Residency, University of California
Internship, University of California
MD, Mount Sinai School of Medicine of New York City
Publications

Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas
Ijare, OB, Hambarde, S, Brasil Da Costa, FH, Lopez, S, Sharpe, MA, Helekar, SA, Hangel, G, Bogner, W, Widhalm, G, Bachoo, RM, Baskin, DS & Pichumani, K 2022, , Neuro-oncology, vol. 24, no. 4, pp. 556-568. https://doi.org/10.1093/neuonc/noab219

Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target
Abdelfattah, N, Kumar, P, Wang, C, Leu, J-S, Flynn, WF, Gao, R, Baskin, DS, Pichumani, K, Ijare, OB, Wood, SL, Powell, SZ, Haviland, DL, Parker Kerrigan, BC, Lang, FF, Prabhu, SS, Huntoon, KM, Jiang, W, Kim, BYS, George, J & Yun, K 2022, , Nature Communications, vol. 13, no. 1. https://doi.org/10.1038/s41467-022-28372-y

Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target
Abdelfattah, N, Kumar, P, Wang, C, Leu, JS, Flynn, WF, Gao, R, Baskin, DS, Pichumani, K, Ijare, OB, Wood, SL, Powell, SZ, Haviland, DL, Parker Kerrigan, BC, Lang, FF, Prabhu, SS, Huntoon, KM, Jiang, W, Kim, BYS, George, J & Yun, K 2022, , Nature Communications, vol. 13, no. 1, 767. https://doi.org/10.1038/s41467-022-28372-y

Indolent multicentric chordoma - A previously undescribed entity: A Case report and literature review
Jenson, AV, Taylor, DG, Ayala, A, Jackson, RE & Baskin, DS 2022, , Surgical Neurology International, vol. 13. https://doi.org/10.25259/SNI_507_2022

Method for noninvasive whole-body stimulation with spinning oscillating magnetic fields and its safety in mice
Hambarde, S, Nguyen, L, Manalo, J, John, B, Baskin, DS & Helekar, SA 2022, , Electromagnetic Biology and Medicine, vol. 41, no. 4, pp. 419-428. https://doi.org/10.1080/15368378.2022.2127108

Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells
Sharpe, MA, Baskin, DS, Pichumani, K, Ijare, OB & Helekar, SA 2021, , Frontiers in Oncology, vol. 11, 768758. https://doi.org/10.3389/fonc.2021.768758

Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells
Sharpe, MA, Baskin, DS, Pichumani, K, Ijare, OB & Helekar, SA 2021, , Frontiers in Oncology, vol. 11, 768758. https://doi.org/10.3389/fonc.2021.768758

Hijacking sexual immuno-privilege in GBM-an immuno-evasion strategy
Sharpe, MA, Baskin, DS, Jenson, AV & Baskin, AM 2021, , International journal of molecular sciences, vol. 22, no. 20, 10983. https://doi.org/10.3390/ijms222010983

METHOD AND APPARATUS FOR ONCOMAGNETIC TREATMENT
Helekar, SA, Baskin, DS, Sharpe, MA & Pichumani, K Sep. 22 2021, , Patent No. EP3880299.

Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas
Ijare, OB, Hambarde, S, Brasil Da Costa, FH, Lopez, S, Sharpe, MA, Helekar, SA, Hangel, G, Bogner, W, Widhalm, G, Bachoo, RM, Baskin, DS & Pichumani, K 2021, , Neuro-oncology, vol. 24, no. 4, https://doi.org/10.1093/neuonc/noab219, pp. 1-13. https://doi.org/10.1093/neuonc/noab219

Regulation | Monoamine oxidases
Raghavan, S, Baskin, DS & Sharpe, MA 2021, . in Encyclopedia of Biological Chemistry: Third Edition. vol. 1, Elsevier, pp. 542-560. https://doi.org/10.1016/B978-0-12-819460-7.00343-1

Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device
Baskin, DS, Sharpe, MA, Nguyen, L & Helekar, SA 2021, , Frontiers in Oncology, vol. 11, 708017. https://doi.org/10.3389/fonc.2021.708017

The leloir cycle in glioblastoma: Galactose scavenging and metabolic remodeling
Sharpe, MA, Ijare, OB, Baskin, DS, Baskin, AM, Baskin, BN & Pichumani, K 2021, , Cancers, vol. 13, no. 8, 1815. https://doi.org/10.3390/cancers13081815

Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields
Helekar, SA, Hambarde, S, Ijare, OB, Pichumani, K, Baskin, DS & Sharpe, MA 2021, , Journal of Cancer Research and Clinical Oncology, vol. 147, no. 12, pp. 3577-3589. https://doi.org/10.1007/s00432-021-03787-0

Elevated levels of circulating betahydroxybutyrate in pituitary tumor patients may differentiate prolactinomas from other immunohistochemical subtypes
Ijare, OB, Holan, C, Hebert, J, Sharpe, MA, Baskin, DS & Pichumani, K 2020, , Scientific Reports, vol. 10, no. 1, 1334. https://doi.org/10.1038/s41598-020-58244-8

MP-Pt(IV): A MAOB-sensitive mitochondrial-specific prodrug for treating glioblastoma
Raghavan, S, Baskin, DS & Sharpe, MA 2020, , Molecular Cancer Therapeutics, vol. 19, no. 12, pp. 2445-2453. https://doi.org/10.1158/1535-7163.MCT-20-0420

MP-Pt(IV): A MAOB-sensitive mitochondrial-specific prodrug for treating glioblastoma
Raghavan, S, Baskin, DS & Sharpe, MA 2020, , Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.MCT-20-0420

Posterior Reversible Encephalopathy Syndrome After Transsphenoidal Resection of Pituitary Macroadenoma
Wong, M, Rajendran, S, Bindiganavile, SH, Bhat, N, Lee, AG & Baskin, DS 2020, , World neurosurgery, vol. 142, pp. 171-175. https://doi.org/10.1016/j.wneu.2020.06.136

The History of Neurosurgery at Houston Methodist Hospital
Grossman, RG, Lee, J, Baskin, DS, Harper, R & Britz, GW 2020, , World neurosurgery, vol. 142, pp. 283-290. https://doi.org/10.1016/j.wneu.2020.06.194

A ”clickable” probe for active MGMT in glioblastoma demonstrates two discrete populations of MGMT
Raghavan, S, Baskin, DS & Sharpe, MA 2020, , Cancers, vol. 12, no. 2, 453. https://doi.org/10.3390/cancers12020453